# Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

> **NCT01043601** · PHASE2 · WITHDRAWN · sponsor: **Pearl Therapeutics, Inc.**

## Conditions studied

- COPD

## Interventions

- **DRUG:** Inhaled PT005
- **DRUG:** Inhaled Placebo
- **DRUG:** Formoterol Fumarate 12 µg (Foradil Aerolizer)

## Key facts

- **NCT ID:** NCT01043601
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-07
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Similar data obtained in another study \[see NCT01085045\], therefore study not implemented.
- **Last updated:** 2014-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01043601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01043601, "Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01043601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*